School Trustee Candidates Across Two Regions Outline Plans

4 sourcesUpdated Oct 23, 20261 min read

0

School Trustee Candidates Across Two Regions Outline Plans — Photo: Valeria Palesska / Wikimedia Commons (Pexels)

Sponsored

School board trustee candidates in two communities are emphasizing practical student support and stronger connections between schools and their communities. In South PEC, former Loyalist College instructor Peter Wheeler says he would focus on academic supports, career readiness, workplace experience and helping students understand postsecondary options. In Chico Unified School District’s Trustee Area 5 race, incumbent Caitlin Dalby highlights teacher advocacy, particularly in special education, while Amy Ford stresses representing families and drawing on her experience as both an educator and parent. Fellow candidate Lance Atkins says he would prioritize civil discourse and consensus-building, bringing experience in local agriculture, coaching and community involvement.

Sponsored

In this story:

More on this story

Back to News

Health

China approves Lilly weight-loss pill, ahead of Novo

China approved Eli Lilly’s once-daily oral weight-loss drug orforglipron, making Lilly the first company with an approved GLP-1 weight-loss pill in the country and giving it an early advantage over Novo Nordisk. The pill will compete with injectable treatments from Novo, Pfizer and Innovent as demand for obesity treatments grows; Novo’s oral Wegovy is not yet approved in China.

14 sources

Business

Lilly’s Foundayo eases sleep apnea in two trials

2

Total sources4

Last updatedOct 23, 2026

Does this breakdown look right?

Sponsored

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

Eli Lilly says its obesity pill Foundayo reduced obstructive sleep apnea in two late-stage trials and plans to seek U.S. approval for the use by year-end, though results suggest it may be less effective than the company’s Zepbound injection. Other potential treatments are advancing, including Pfizer’s recruiting Phase 3 trial of a monthly injection and Incannex’s oral therapy, which showed promising results in an earlier-stage study.

9 sources

Sponsored

Business

Lilly, Hims Partner to Offer Obesity Drugs

Lilly and Hims will offer Zepbound from $299/month and Foundayo from $149/month on Hims as of Nov. 6, 2026, with Hims barring compounded Lilly knockoffs.

17 sources